Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57) Last modified January 2015.

Slides:



Advertisements
Similar presentations
Emergency Care Part 2: Treating and Preventing Hypoglycaemia
Advertisements

Unstable angina and NSTEMI
Inadvertent perioperative hypothermia
Implementing NICE guidance
Attention deficit hyperactivity disorder Implementing NICE guidance 2008 NICE clinical guideline 72.
Implementing NICE guidance
Depression in adults with a chronic physical health problem
Implementing NICE guidance
Drug treatment for chronic hepatitis B Implementing NICE guidance NICE technology appraisal guidance 96, 153, 154, 173 Updated 2009.
Implementing NICE guidance
Respiratory tract infections - antibiotic prescribing
Familial hypercholesterolaemia
Type 2 diabetes Implementing NICE guidance 2009 NICE clinical guideline 87.
Apr-15 Insulin Pump Therapy – A Shared Journey Heather Maxwell Diabetes Specialist Nurse Insulin Pump Service Greater Glasgow & Clyde.
A lady with vomiting. A 23-year-old female student presents to her GP 5 days after returning from a ski holiday. She developed what she thought was a.
National Diabetes Audit (NDA) PARTNERSHIP WORKING WITH PATIENTS AND SERVICE USERS Laura Fargher Diabetes UK.
Osteoarthritis Implementing NICE guidance 2008 NICE clinical guideline 59.
National Diabetes Programme 2013 Ronan Canavan National Diabetes Programme NAGP AGM 23 rd Nov 2013.
Low back pain Implementing NICE guidance 2009 NICE clinical guideline 88.
Algorithm for the Treatment and Management of Hypoglycaemia in Adults with Diabetes Mellitus in Hospital Hypoglycaemia is a serious condition and should.
Insulin Pump What to tell your patient!! Prakash Abraham Isla Fairley.
Copyright © 2008 Delmar. All rights reserved. Chapter 21 Populations with Chronic Diseases.
Diabetes Mellitus Type 2
Type 1 Diabetes Debbie McCausland Paediatric Diabetes Specialist Nurses.
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Implementing NICE guidance February 2011 NICE clinical.
Developing a National Paediatric Diabetes Plan: What are the key issues for education? Dr. Sheridan Waldron HCP Education Lead for Children and Young people.
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Diabetes and PVD.
Documented history-Bladder Our Site:
Implementing NICE guidance
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Adult Medical-Surgical Nursing
Implementing NICE guidance
Management of Adults with Diabetes undergoing Surgery and Elective Procedures UHL Guideline – April 2013 The aim of the guideline is to improve standards.
Dr. Turki AlBatti,MD. barriers in young adults with type 1 diabetes Glycemic control and adherence behaviors remain low for patients with type 1 diabetes.
An Innovative Approach to Managing Diabetes in a Large Public Health System Donna J. Calvin, PhD, FNP-BC, CNN Post Doctoral Research Associate University.
Marta Alves, Celestino Neves, Ana Varela, Cristina Arteiro, Luís Miguel Pereira, Davide Carvalho, José Luís Medina. Endocrinology Service, S. João Hospital,
Who should access pump therapy? UK perspective Dr Thomas Ulahannan International Diabetes Federation European Region General Assembly Together We Are Stronger.
Improving Inpatient Safety by Standardizing Care Ruth Miller Lead Nurse Diabetes Service Royal Free Hospital Foundation Trust February 2014.
Childhood diabetes St Vincent Declaration Report from the 10th Anniversary St Vincent Declaration meeting.
Glucose Control and Monitoring
Implementing NICE guidance 2011 NICE clinical guideline 113 Generalised anxiety disorder in adults.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Heavy menstrual bleeding Implementing NICE guidance January 2007 NICE clinical guideline 44.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
Alcohol dependence and harmful alcohol use NICE quality standard August 2011.
What is Diabetes? Definition: A disorder of metabolism where the pancreas produces little or no insulin or the cells do not respond to the insulin produced.
Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Date of download: 6/26/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Diabetes Mellitus By Lynnette Jarvis. What is diabetes mellitus?  A chronic condition associated with abnormally high blood sugar  Results from either.
Dr Mohammed Babsail, Dr Bhavin Bakrania
To Pump OR To Inject … that is the Question … ?
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
National Diabetes Insulin Pump Audit,
Key publication slides
National Diabetes Audit – An Overview
Key publication slides
HbA1c as a Marker of Glycaemic Control in Diabetes Care
Diabetes Mellitus.
Insulin Pump Therapy – A Shared Journey
National Diabetes Insulin Pump Audit,
Monitoring in Type 2 Diabetes
Type 2 diabetes.
Treatment Pathway for Adults with Type 1 Diabetes
Principal recommendations
Campbell FM, et al. Pediatr Diabetes. 2018;19(7):1294–1301
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
Hyperglycemic Targets & Hypoglycemia
Presentation transcript:

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57) Last modified January 2015 Implementing NICE guidance NICE technology appraisal guidance TA151

What this presentation covers Definitions Background Clinical need Recommendations Barriers to treatment Costs and savings Discussion

Updated guidance This guidance replaces ‘NICE technology appraisal guidance 57’ issued in February The Institute reviews each piece of guidance it issues. There has been a change to the recommendation on the use of CSII in children younger than 12 years. Units for reporting HbA1c have changed from % to mmol/mol since this guidance was published.

Definitions CSII – Continuous subcutaneous insulin infusion Disabling hypoglycaemia – repeated and unpredictable occurrence of hypoglycaemia which results in persistent anxiety about recurrence associated with a significant adverse effect on quality of life Hyperglycaemia – high blood glucose levels Hypoglycaemia – low blood glucose levels MDI – multiple daily injection

Background 250,000 people in the UK have type 1 diabetes UK has variable access and provision of CSII therapy Current UK usage of insulin pumps is low Estimated insulin pump usage in different countries (J Pickup) Graph reproduced courtesy of Diabetes UK

Diabetes mellitus A chronic metabolic disorder caused by: insufficient activity of the hormone insulin (either a lack of insulin, or resistance to its action) and subsequent loss of control of blood glucose levels. Image reproduced courtesy of Diabetes UK

Diabetes mellitus symptoms and problems Short term acute metabolic emergencies that can be life-threatening: - diabetic ketoacidosis; and - hypoglycaemia caused by treatment Long term nephropathy renal failure ischaemic heart disease stroke foot ulceration and amputation

Recommendation: Adults and children 12 years and older attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) result in the person experiencing disabling hypoglycaemia or HbA1c levels have remained high (8.5% [69 mmol/mol] or above) on MDI therapy despite a high level of care. Insulin pump therapy is recommended as a treatment option for adults and children 12 years and older with type 1 diabetes provided:

Recommendation: Adults and children 12 years and older Only continue CSII therapy if it results in a sustained improvement in glycaemic control evidenced by: a fall in HbA1c levels or a sustained decrease in the rate of hypoglycaemic episodes

Recommendation: Children younger than 12 years MDI therapy is considered to be impractical or inappropriate, and children on insulin pumps would be expected to undergo a trial of MDI therapy between the ages of 12 and 18 years. CSII therapy is recommended as a treatment option for children younger than 12 years with type 1 diabetes provided:

Recommendation: Type 2 diabetes CSII therapy is not recommended for the treatment of people with type 2 diabetes mellitus

Recommendation: Specialist teams CSII therapy should be initiated only by a trained specialist team comprising: a physician with a specialist interest in insulin pump therapy a diabetes specialist nurse a dietician.

Insulin pump technology Insulin pump models currently available: Animas 2020 Paradigm real-Time MMT-522 Paradigm real-Time MMT-722 Accu-Chek Spirit Accu-Chek D-Tron Plus Deltec Cozmo Image reproduced courtesy of Diabetes UK

Barriers to treatment Inconsistent or incomplete provision of conventional diabetes management Unclear referral pathways; lack of formal CSII pump assessments Costs of devices range from £996 to £2750 Uneven provision of specialist CSII services

Costs and savings per 100,000 population Estimated costs and savings CSII pump therapy Costs (£000s per year) Estimated cost of providing CSII72.4 Savings (£000s per year) Estimated saving resulting from reduction in MDI24 Additional annual recurrent cost of providing continuous subcutaneous insulin infusion compared with MDI 48.4

For discussion Which recommendations will require a change in practice? What is the current availability of insulin pump therapy locally? How could we enable the full CSII therapy patient pathway, including maintenance to be provided locally? What additional training is needed?

Find out more Visit for: Other guideline formats Costing report and template Audit support Slide set